透明细胞型肝细胞癌:Gd-EOB-DTPA增强MR影像特征与预后
回顾性分析42例透明细胞型肝细胞癌(CCHCC)与84例年龄匹配的非特指型肝细胞癌(NOS-HCC)的Gd-EOB-DTPA增强MRI特征及预后,发现CCHCC脂肪含量更多、Edmondson分级相对更高,增强前T1WI及肝胆期的病灶-肌肉比与病灶-肝比显著更高;脂肪含量与增强前T1WI的病灶-肝比联合预测CCHCC的AUC为0.750;两组临床结局无统计学显著差异。
要点
- CCHCC较NOS-HCC更常见脂肪含量(P<0.001),Edmondson肿瘤分级相对更高(P=0.001)。
- 增强前T1WI及肝胆期CCHCC的病灶-肌肉比与病灶-肝比均显著高于NOS-HCC。
- 脂肪含量联合增强前T1WI病灶-肝比预测CCHCC的AUC为0.750,优于单一指标。
核心结论
- 脂肪含量及增强前T1WI与肝胆期的校正病灶信号强度可用于鉴别CCHCC与NOS-HCC,CCHCC预后与NOS-HCC相似。
研究设计与样本
- 回顾性分析2015年1月至2021年10月42例CCHCC与84例年龄匹配NOS-HCC患者的临床、病理及Gd-EOB-DTPA增强MRI资料,采用单因素及多因素logistic回归和Cox回归分析。
关键影像表现/征象
- CCHCC较NOS-HCC更常见脂肪含量(P<0.001),Edmondson肿瘤分级相对更高(P=0.001)。
- 增强前T1WI上CCHCC的病灶-肌肉比(P=0.001)与病灶-肝比(P=0.003)均显著高于NOS-HCC。
- 肝胆期CCHCC的病灶-肌肉比(P=0.007)与病灶-肝比(P=0.048)均显著高于NOS-HCC。
诊断标准与关键数值
- 脂肪含量预测CCHCC的AUC为0.678。
- 增强前T1WI病灶-肝比预测CCHCC的AUC为0.666。
- 脂肪含量联合增强前T1WI病灶-肝比预测CCHCC的AUC为0.750。
临床应用与阅片要点
- 阅片时可关注增强前T1WI及肝胆期的病灶-肌肉比与病灶-肝比,CCHCC倾向于更高。
- 脂肪含量与增强前T1WI病灶-肝比联合有助于鉴别CCHCC与NOS-HCC。
- CCHCC患者中肿瘤大小>2 cm及强化包膜是DFS与OS的独立预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate imaging findings on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-enhanced MRI) and prognosis of clear cell hepatocellular carcinoma (CCHCC) comparing with non-otherwise specified hepatocellular carcinoma (NOS-HCC).
METHODS: The clinical, pathological and MR imaging features of 42 patients with CCHCC and 84 age-matched patients with NOS-HCC were retrospectively analyzed from January 2015 to October 2021. Univariate and multivariate logistic regression and Cox regression analyses were performed to identify independent diagnostic and prognostic factors for CCHCC. Disease-free survival (DFS) and overall survival (OS) were determined by Kaplan-Meier analysis.
RESULTS: CCHCC showed fat content more frequently (P < 0.001) and relatively higher Edmondson tumor grade (P = 0.001) compared with NOS-HCC. The lesion-to-muscle ratio (LMR) and lesion-to-liver ratio (LLR) of CCHCC on pre-enhancement T1-weighted imaging (pre-T1WI) (P = 0.001, P = 0.003) and hepatobiliary phase (HBP) (P = 0.007, P = 0.048) were significantly higher than those of NOS-HCC. The area under the curve (AUC) for fat content, LLR on pre-T1WI and their combination with better diagnostic performance in predicting CCHCC were 0.678, 0.666, and 0.750, respectively. There was no statistically significant difference in clinical outcomes between CCHCC and NOS-HCC. Multivariate Cox analysis confirmed that tumor size > 2 cm and enhancing capsule were independent prognostic factors for DFS and OS among CCHCC patients.
CONCLUSION: Fat content and adjusted lesion signal intensity on pre-T1WI and HBP could be used to differentiate CCHCC from NOS-HCC. CCHCC had similar prognosis with NOS-HCC.
引用
- Song M, Tao Y, He K, et al. Clear cell hepatocellular carcinoma: Gd-EOB-DTPA-enhanced MR imaging features and prognosis. Abdom Radiol (NY). 2024. PMID: 38557768. doi:10.1007/s00261-024-04263-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。